GSS Share Price Performance
AU$0.31
-0.44 (-58.67%)
Price AU$0.31
Share PriceAU$0.31
GSS Community Narratives
There are no narratives available yet.
Recent GSS News & Updates
No updates
Genetic Signatures Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.099
- Gross Margin
- 53.24%
- Net Profit Margin
- -121.06%
- Debt/Equity Ratio
- 0%
Genetic Signatures Limited Competitors
About GSS
- Founded
- 2001
- Employees
- n/a
- CEO
- WebsiteView website
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, SARS-CoV-2 respiratory plus, coronavirus, atypical respiratory, pertussis and PCP, parainfluenza 4, STI genital pathogen, extended spectrum beta-lactamase and carbapenemase producing organisms, viral meningitis, flavivirus dengue alphavirus, flavivirus reflex, dengue typing, and alphavirus reflex Detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.
Australian Market Performance
- 7 Days: 1.2%
- 3 Months: 7.7%
- 1 Year: 15.0%
- Year to Date: 7.3%
Over the last 7 days, the market has risen 1.2%, driven by gains of 4.0% in the Materials sector. In the last year, the market has climbed 15%. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading